Posted by Michael Wonder on 04 May 2017
ICER releases draft evidence report on treatments for osteoporosis, including abaloparatide and romosozumab
3 May 2017 - Abaloparatide recently approved by FDA, romosozumab under FDA review; public comment and requests to give oral comment now being accepted until May 31.
The Institute for Clinical and Economic Review (ICER) has released a draft evidence report assessing the comparative clinical effectiveness and value of three treatments for osteoporosis in post-menopausal women: abaloparatide (Tymlos, Radius Health, Inc.), romosozumab (Amgen and UCB), and teriparatide (Forteo, Eli Lilly.).
Abaloparatide was approved by the FDA last week, and romosozumab is currently under FDA review, with an with approval decision expected in July of 2017. ICER's report and accompanying draft voting questions are now open to public comment for four weeks.
